Anlotinib for Esophageal Cancer (AFEC)

Esophageal Cancer Clinical Trial

Official title:

A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Esophageal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04966611
• Other study ID #: AZLL022020001200116
• Status: Recruiting
• Start date: July 15, 2021
• Est. completion date: July 15, 2024

Study information

• Verified date: July 2021
• Source: Anyang Tumor Hospital
• Contact: Junsheng Mr Wang, doctor
• Phone: 0086-15950527350
• Email: junsheng20210616[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: July 15, 2024
• Est. primary completion date: July 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Age: = 18 years old, male or female;

2. Patients with esophageal cancer were diagnosed;

3. Patients assessed by doctors to benefit from single or combined treatment of arotinib;

4. Patients volunteered to join the project.

Exclusion Criteria:

None

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Drug:
• Anlotinib
This is an observational study

Locations

Country	Name	City	State
China	Anyang Cancer Hospital	Anyang

Sponsors (1)

Lead Sponsor	Collaborator
Anyang Tumor Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	OS	Overall Survival	From date of admission until the date of death from any cause, assessed up to 24 months
Secondary	PFS	Progression Free Survival	From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months